Interleukin-1 beta: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Michal Harel (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='350' side='right' scene='57/571319/Scene1/1' caption='HUMAN INTERLEUKIN-1 β (PDB code [[9ilb]])'> | |||
== Interleukin-1 beta(IL-1β) == | == Interleukin-1 beta(IL-1β) == | ||
IL-1β along with IL-1α cytokines secreted from local inflammatory cells, are belong to IL-1 family.[1] The former is dominate (90% of Interleukin-1) and the two cytokines could be distinguished by the cells with which they interact. IL-1β precursor(31KDa) need to be activated by protease (convertase or IL-1β converting enzyme[2]) to form IL-1 active species(17KDa)[3]. The active mature IL-1 cytokines could mediate a large range of biological activities such as innate and adaptive immunity as well as bio-components of the acute phase reaction, including the febrile response, secretion of adrenocorticotropic hormone (ACIH), and the synthesis of [http://en.wikipedia.org/wiki/Acute-phase_protein acute phase proteins]. | IL-1β along with IL-1α cytokines secreted from local inflammatory cells, are belong to IL-1 family.[1] The former is dominate (90% of Interleukin-1) and the two cytokines could be distinguished by the cells with which they interact. IL-1β precursor(31KDa) need to be activated by protease (convertase or IL-1β converting enzyme[2]) to form IL-1 active species(17KDa)[3]. The active mature IL-1 cytokines could mediate a large range of biological activities such as innate and adaptive immunity as well as bio-components of the acute phase reaction, including the febrile response, secretion of adrenocorticotropic hormone (ACIH), and the synthesis of [http://en.wikipedia.org/wiki/Acute-phase_protein acute phase proteins]. | ||
| Line 48: | Line 47: | ||
[7] Hou J, '''Design of a superior cytokine antagonist for topical ophthalmic use''',[http://www.pnas.org/content/110/10/3913.full.pdf Proc Natl Acad Sci USA,2013,110,3913-3918.] | [7] Hou J, '''Design of a superior cytokine antagonist for topical ophthalmic use''',[http://www.pnas.org/content/110/10/3913.full.pdf Proc Natl Acad Sci USA,2013,110,3913-3918.] | ||
</StructureSection> | |||